Drug-Drug Interactions in Patients with COVID-19: A Retrospective Study at a Tertiary Care Hospital in Eastern India.

Introduction

Concomitant atrial fibrillation (AF) in non-ST segment elevation acute coronary syndrome (NSTE-ACS) patients complicates the decision-making process regarding short- and long-term antithrombotic strategies. Patient profiles and usage rates of different antithrombotic combinations in this patient subgroup in Romania are poorly described.

Introduction

Coronavirus disease 2019 (COVID-19) is an emerging viral infection without any approved treatment. Investigational therapies for COVID-19 may cause clinically important drug-drug interactions (DDIs). We aimed to study drug-drug interactions (DDIs) and their risk factors in hospitalised COVID-19 patients.

Methods

We conducted a retrospective study in a tertiary care hospital dedicated to COVID-19 patients. The Lexi-Interact database was used to investigate clinically important DDIs. The database output, including interacting drug pairs, risk rating, reliability rating, mechanism, and management, was evaluated.

Results

Medical records of 200 COVID-19 patients were analysed. All patients had at least one clinically important DDI. More than half of interactions were associated with hydroxychloroquine and azithromycin, the most commonly prescribed medications for the management of COVID-19. Concomitant drugs for comorbid conditions leading to polypharmacy were significantly associated with the occurrence of this.

Conclusion

There is a higher chance of DDI, which necessitates ongoing care evaluation and therapy adjustment. Drugs used to treat COVID-19 should be carefully selected.